Status:
COMPLETED
Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients
Lead Sponsor:
Endocrine Research Society
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
Purpose: To assess prior need for lipid lowering therapy in patients with type 2 diabetes. Background/Hypothesis: At present, lipid lowering therapy, usually with a HMG-CoA reductase inhibitor or "...
Eligibility Criteria
Inclusion
- LDL \< 2.5 mmol/L and total cholesterol: HDL-cholesterol ratio \< 4.0
- Blood pressure ≤ 130/80 mmHg
- No personal or family history of CVD
- No history of proteinuria or renal failure
- Taking atorvastatin (lipitor) with a dosage ≤ 10 mg, equivalent dosages for other statins follow this requirement (Simvastatin ≤ 20 mg, pravastatin ≤ 40 mg, rosuvastatin ≤ 5 mg, fluvastatin ≤ 40 mg and lovastatin ≤ 40 mg)
- Calculated by the UKPDS Risk Engine to be low risk (risk is less than 15%) for Coronary Heart Disease (CHD), fatal CHD, stroke and fatal stroke (the UKPDS Risk Engine provides risk estimates in individuals with type 2 diabetes not known to have heart disease (1), calculating the patient's risk involves considering risk factors such as age, sex, incidence of smoking and lipid levels)
Exclusion
- Patients who do not meet the above criteria or are not willing to participate will not be included in the study
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00639080
Start Date
March 1 2008
End Date
October 1 2010
Last Update
July 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrine Research Society
Vancouver, British Columbia, Canada, V6E 1M7